Monroe Carell Jr. Children’s Hospital at Vanderbilt has launched a study to determine the impact of a predictive model for identifying pediatric patients at risk for developing blood clots or venous thromboembolisms (VTEs).

Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson’s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.

A protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis prevents the activation of an innate immune response that leads to cell death, Vanderbilt researchers have discovered.

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.